Use the hyperlinks, where available to access additional clinical trial information.
A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C Melanoma
Melanoma Institute Australia
Eligible patients will be randomised to receive one of three combination treatments: (1) Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day for 1 week, then followed by treatment with Pembrolizumab 2mg/kg delivered intravenously at weeks 1, 3, and 6, then once every 3 weeks from week 6 for 46 weeks. (2) Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day + Pembrolizumab 200mg intravenously once every 3 weeks for 6 weeks, then Pembrolizumab alone for 46 weeks. OR (3)Pembrolizumab 200mg intravenously once every 3 weeks alone for 52 weeks.